Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fasted Conditions
NCT ID: NCT01367652
Last Updated: 2018-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
28 participants
INTERVENTIONAL
2008-03-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalency Study of Letrozole 2.5 mg Tablets Under Fed Conditions
NCT01367626
Bioavailability Study of Letrozole Tablets 2.5 mg of Dr.Reddy's Under Fed Conditions
NCT01372982
Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions
NCT01331421
An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg
NCT00291109
Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg
NCT00648063
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Letrozole
2.5 mg tablet
Letrozole
2.5 mg Tablet
Femara
2.5 mg tablet
Letrozole
2.5 mg tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Letrozole
2.5 mg tablet
Letrozole
2.5 mg Tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment with known enzyme altering drugs.
* History of allergic or adverse response to letrozole or any comparable or similar product.
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roxane Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan Copa, PharmD
Role: PRINCIPAL_INVESTIGATOR
PRACS Institute, Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PRACS Institute, Ltd.
Fargo, North Dakota, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LETR-T25-PVFS-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.